|
Thursday 4th May 2023 |
Text too small? |
AFT Pharmaceuticals (NZX: AFT , ASX: AFP) announced today that it intends to release on Monday May 22 2023 its full year results for the year ended March 31 2023. The release will be issued at around 09:00.
This will be followed by a presentation by management at 10:00 by teleconference. The presentation material which will be referred to by management will be issued at around 09:00 and will also be available on the company’s website aftpharm.com.
To attend the conference call you will need to use the pre-registration link below. Once you have completed this you will be provided with dial in details and a unique pin code.
Registration Link: AFT results presentation FY2023
For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.
For more information:
Investors Media
Malcolm Tubby Richard Inder
CFO, AFT Pharmaceuticals Ltd The Project
Phone: +64 9 488 0232 Phone: 021 645 643
Email: malcolm@aftpharm.com Email: richard@theproject.co.nz
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of the world. For more information: aftpharm.com
No comments yet
AIR - Air New Zealand market update
May 14th Morning Report
PEB - Pacific Edge Placement Increased to NZ$25.4 Million
Radius Care Reports Earnings Growth and 50% Higher Dividend
May 13th Morning Report
Pacific Edge launches capital raise of NZ$24 million
SML - Resignation of Synlait Director
FBU - Sale of Laminex Cheltenham property
CVT - Comvita Achieves Minimum Capital Raise Requirement
Devon Funds Morning Note - 04 May 2026